| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Moxifloxacin HCl (formerly BAY12-8039; BAY12-8039; BAY 12-8039; Avelox, Avalox, Avelon, Vigamox, Moxeza),the hydrochloride salt of moxifloxacin, is an orally bioactive, broad spectrum and 4th generation antibacterial drug of the fluoroquinolone class with high activity against both Gram positive and Gram negative bacteria. It functions as a topoisomerase II and IV DNA inhibitor.
| Targets |
Topoisomerase II; Topoisomerase IV
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
The antibiotic agent doxifloxacin (hydrochloride) is a synthetic fluoroquinolone. When compared to earlier fluoroquinolone agents, antibacterial doxifloxacin, an extended-spectrum fluoroquinolone, exhibits better coverage against gram-positive cocci and atypical pathogens while maintaining good activity against gram-negative bacteria. All common upper and lower respiratory tract pathogens are included in moxifloxacin's antibacterial spectrum, making it one of the most effective fluoroquinolones against pneumococci, including strains resistant to macrolides and penicillin. Moxifloxacin's potential for phototoxicity is limited. Moxifloxacin demonstrated bacteriologic eradication rates of 90–97% and clinical success rates of 88–97% in clinical trials. Moxifloxacin is an antimicrobial agent that is both safe and effective in treating community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, and acute sinusitis. As shown by the production of MDA and the prolongation of survival, movifloxacin may promote lipid peroxidation and improve phagocytosis without being toxic, as shown by the white blood cell count. Clinical recommendations: Acute sinusitis, bacterial infection, acute bronchitis, and abdominal abscess toxicity CNS and gastrointestinal side effects, such as reduced activity, sleepiness, trembling, convulsions, vomiting, and diarrhea, are signs of an overdose. In rats and mice, a minimal lethal intravenous dose is 100 mg/kg.
|
|
| Animal Protocol |
144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia
12 mg/kg Intravenous injection; once per day, twice per day, three times per day; for 7 days |
|
| References |
| Molecular Formula |
C21H24FN3O4.HCL
|
|
|---|---|---|
| Molecular Weight |
437.89
|
|
| Exact Mass |
437.15
|
|
| Elemental Analysis |
C, 57.60; H, 5.75; Cl, 8.10; F, 4.34; N, 9.60; O, 14.61
|
|
| CAS # |
186826-86-8
|
|
| Related CAS # |
151096-09-2；192927-63-2
|
|
| Appearance |
Solid powder
|
|
| SMILES |
COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
|
|
| InChi Key |
IDIIJJHBXUESQI-DFIJPDEKSA-N
|
|
| InChi Code |
InChI=1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1
|
|
| Chemical Name |
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2837 mL | 11.4184 mL | 22.8368 mL | |
| 5 mM | 0.4567 mL | 2.2837 mL | 4.5674 mL | |
| 10 mM | 0.2284 mL | 1.1418 mL | 2.2837 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05660720 | Active Recruiting |
Drug: Orelabrutinib and placebo (orelabrutinib tablet simulator) Drug: Orelabrutinib |
Healthy Subject | Beijing InnoCare Pharma Tech Co., Ltd. |
November 19, 2022 | Phase 1 |
| NCT05924815 | Active Recruiting |
Drug: Aficamten Drug: Moxifloxacin |
Healthy Participants | Cytokinetics | May 15, 2023 | Phase 1 |
| NCT03236961 | Active Recruiting |
Drug: Ertapenem Drug: Moxifloxacin |
Acute Appendicitis | Turku University Hospital | April 3, 2017 | Not Applicable |
| NCT05878522 | Active Recruiting |
Drug: moxifloxacin Drug: placebo |
Healthy | Pfizer | May 15, 2023 | Phase 1 |
| NCT04179500 | Active Recruiting |
Drug: moxifloxacin Drug: pyrazinamide |
Tuberculosis, MDR Tuberculosis |
Global Alliance for TB Drug Development |
September 16, 2021 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA